Quick Answer
AbbVie Inc. reported Total Revenue of $61.16 billion for fiscal year 2025.
AbbVie Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $61.16B +8.6% |
$56.33B +3.7% |
$54.32B -6.4% |
$58.05B +3.3% |
$56.20B +22.7% |
$45.80B +37.7% |
| Net Income | $4.23B -1.2% |
$4.28B -12.0% |
$4.86B -58.9% |
$11.84B +2.5% |
$11.54B +150.0% |
$4.62B -41.4% |
| Diluted EPS | $2.36 -1.3% |
$2.39 -12.1% |
$2.72 -59.0% |
$6.63 +2.8% |
$6.45 +137.1% |
$2.72 -48.5% |
| Total Assets | $133.96B -0.9% |
$135.16B +0.3% |
$134.71B -2.9% |
$138.81B -5.3% |
$146.53B -2.7% |
$150.56B +69.0% |
| Cash and Equivalents | $5.23B -5.3% |
$5.52B -56.9% |
$12.81B +39.3% |
$9.20B -5.6% |
$9.75B +15.4% |
$8.45B -78.8% |
| Stockholders Equity | -$3.27B -198.3% |
$3.33B -67.9% |
$10.36B -40.0% |
$17.25B +12.0% |
$15.41B +17.8% |
$13.08B +260.0% |
| Operating Income | $15.07B +65.0% |
$9.14B -28.4% |
$12.76B -29.6% |
$18.12B +1.1% |
$17.92B +57.7% |
$11.36B -12.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $15.78B | +9.1% | +2.3% |
| Net Income | September 30, 2025 | $186.00M | -88.1% | -80.2% |
| Diluted EPS | September 30, 2025 | $0.10 | -88.6% | -80.8% |
| Total Assets | September 30, 2025 | $133.90B | -6.6% | -2.4% |
| Cash and Equivalents | September 30, 2025 | $5.63B | -22.4% | -13.0% |
| Stockholders Equity | September 30, 2025 | -$2.64B | -143.8% | -1343.7% |
| Operating Income | September 30, 2025 | $1.90B | -50.3% | -61.1% |
- AbbVie Inc. reported Total Revenue of $61.16 billion for fiscal year 2025.
- AbbVie Inc. showed an increase of +8.6% in Total Revenue compared to the prior fiscal year.
- AbbVie Inc. reported Net Income of $4.23 billion for fiscal year 2025.
- AbbVie Inc. showed a decrease of -1.2% in Net Income compared to the prior fiscal year.
- AbbVie Inc. reported Diluted EPS of $2.36 per share for fiscal year 2025.
- AbbVie Inc. showed a decrease of -1.3% in Diluted EPS compared to the prior fiscal year.
- AbbVie Inc. reported Total Assets of $133.96 billion for fiscal year 2025.
- AbbVie Inc. showed a decrease of -0.9% in Total Assets compared to the prior fiscal year.
- AbbVie Inc. reported Cash and Equivalents of $5.23 billion for fiscal year 2025.
- AbbVie Inc. showed a decrease of -5.3% in Cash and Equivalents compared to the prior fiscal year.
- AbbVie Inc. reported Stockholders Equity of -$3.27 billion for fiscal year 2025.
- AbbVie Inc. showed a decrease of -198.3% in Stockholders Equity compared to the prior fiscal year.
- AbbVie Inc. reported Operating Income of $15.07 billion for fiscal year 2025.
- AbbVie Inc. showed an increase of +65.0% in Operating Income compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: